ascopubs.org

Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to ...

Conclusion: ET-743 given by either of these two schedules of administration can induce objective responses in a subset of refractory pts with LMS or LPS. Disease control as demonstrated by stable ...
ascopubs.org

Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized ...

Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study. A phase 1 study of MDM2 ...